Abvc Biopharma Inc (ABVC)
$0.47
Performance
- $0.41$0.56$0.47
12.02%
Downside
Day's Volatility :26.67%
Upside
16.65%
- $0.47$3.35$0.47
0.0%
Downside
52 Weeks Volatility :85.97%
Upside
85.97%
Returns
| Period | Abvc Biopharma Inc | Index (Russel 2000) |
|---|---|---|
3 Months | -31.27% | 0.0% |
6 Months | -52.87% | 0.0% |
1 Year | -39.63% | 0.0% |
3 Years | -97.54% | -20.8% |
Highlights
Market Capitalization | 6.7M |
Book Value | $0.71 |
Earnings Per Share (EPS) | -1.66 |
Wall Street Target Price | 2.02 |
Profit Margin | 0.0% |
Operating Margin TTM | -833.72% |
Return On Assets TTM | -44.55% |
Return On Equity TTM | -320.36% |
Revenue TTM | 136.4K |
Revenue Per Share TTM | 0.02 |
Quarterly Revenue Growth YOY | 1817.5% |
Gross Profit TTM | 350.7K |
EBITDA | -8.5M |
Diluted Eps TTM | -1.66 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | 0.0 |
EPS Estimate Next Year | 0.0 |
EPS Estimate Current Quarter | 0.0 |
EPS Estimate Next Quarter | 0.0 |
Analyst Recommendation
- Current
- 1M Ago
- 3M Ago
Analyst Forecast
What analysts predicted
Upside of 329.79%
Technicals Summary
Sell
Neutral
Buy
Abvc Biopharma Inc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.
Peers
| Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
|---|---|---|---|---|---|
 Abvc Biopharma Inc | -19.73% | -52.87% | -39.63% | -97.54% | -98.2% |
 Regeneron Pharmaceuticals, Inc. | -10.93% | 8.12% | 21.23% | 85.29% | 239.25% |
 Novo Nordisk A/s | -9.85% | -6.35% | 25.79% | 137.8% | 353.05% |
 Alnylam Pharmaceuticals, Inc. | 5.73% | 77.74% | 60.24% | 32.45% | 248.92% |
 Vertex Pharmaceuticals Incorporated | -0.6% | 17.7% | 29.79% | 160.59% | 174.92% |
| Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
|---|---|---|---|---|---|---|---|---|
Abvc Biopharma Inc | NA | NA | NA | 0.0 | -3.2 | -0.45 | NA | 0.71 |
Regeneron Pharmaceuticals, Inc. | 26.81 | 26.81 | 1.38 | 45.04 | 0.17 | 0.08 | NA | 261.41 |
Novo Nordisk A/s | 39.53 | 39.53 | 1.79 | 3.39 | 0.89 | 0.23 | 0.01 | 25.24 |
Alnylam Pharmaceuticals, Inc. | NA | NA | -0.49 | -2.47 | -15.01 | 0.02 | NA | -0.02 |
Vertex Pharmaceuticals Incorporated | 32.84 | NA | 0.56 | 0.33 | -0.03 | 0.13 | NA | 57.26 |
| Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
|---|---|---|---|---|---|
Abvc Biopharma Inc | Sell | $6.7M | -98.2% | NA | 0.0% |
Regeneron Pharmaceuticals, Inc. | Buy | $111.6B | 239.25% | 26.81 | 32.04% |
Novo Nordisk A/s | Buy | $519.8B | 353.05% | 39.53 | 34.84% |
Alnylam Pharmaceuticals, Inc. | Buy | $34.8B | 248.92% | NA | -3.11% |
Vertex Pharmaceuticals Incorporated | Buy | $120.8B | 174.92% | 32.84 | -4.74% |
Insights on Abvc Biopharma Inc
Increasing Revenue
Revenue is up for the last 2 quarters, 1.20K → 117.14K (in $), with an average increase of 99.0% per quarter
Increasing Net Profit
Netprofit is up for the last 2 quarters, -3.93M → -1.01M (in $), with an average increase of 288.4% per quarter
Vs ALNY
In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 60.2% return, outperforming this stock by 99.8%
Vs VRTX
In the last 3 years, Vertex Pharmaceuticals Incorporated has given 33.0% return, outperforming this stock by 130.5%
Institutional Holdings
Geode Capital Management, LLC
0.44%Vanguard Group Inc
0.38%Honkamp Krueger Financial Services Inc
0.31%Citadel Advisors Llc
0.20%Northern Trust Corp
0.15%XTX Topco Ltd
0.15%
Company Information
american brivision (holding) corporation, a clinical stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the united states. the company is developing abv-1501, a combination therapy for triple negative breast cancer; abv-1504 for major depressive disorders; abv-1505 for attention deficit hyperactivity disorder; abv-1703 for the treatment of pancreatic cancer; abv-1702 to treat myelodysplastic syndromes; and abv-1601 for treating depression in cancer patients. it has a co-development agreement with rgene corporation; collaboration agreement with biohopeking corporation to develop abv-1501; and collaborative agreement with biofirst corporation to co-develop bfc-1401 vitreous substitute for vitrectom; and license with biofirst corporation to research and develop a medical device, abv-1701 vitargus for the treatment of retinal detachment or vitreous hemorrhage. the company was founded in 2015 and is based in fremont, california. american br
Organization | Abvc Biopharma Inc |
Employees | 16 |
CEO | Mr. Eugene Jiang |
Industry | Industrial Specialties |
Discover More
Eaton Vance Enh Eqt Inc Ii
$0.47
-11.67%
Aditxt Inc
$0.47
-11.67%
Oportun Financial Corp
$0.47
-11.67%
Yieldmax Tsm Option Income Strategy Etf
$0.47
-11.67%
Innovator International Dvlpd Pwr Bff Etf - August
$0.47
-11.67%
Shoals Technologies Group, Inc.
$0.47
-11.67%
Neos Enhanced Income 1-3 Month T-bill Etf
$0.47
-11.67%
Lakeside Holding Ltd.
$0.47
-11.67%
Allianzim Us Large Cap Buffer20 Nov Etf
$0.47
-11.67%